Accendra Health Suspended From NYSE, Moves to OTC Market Under ACCH
The company said trading in its common stock was suspended effective immediately and the NYSE will begin delisting proceedings, with shares now quoted on the OTCQB.
Stock reaction: ACH shares closed down 3.5% at $0.02 on Nov. 18, from Nov. 17's close of $0.02. The S&P 500 was down 0.3% that day.

Key points
- NYSE suspended trading in Accendra Health (NYSE: ACH) effective immediately and began delisting proceedings
- Shares began trading on the OTCQB under ACCH on Nov. 17, 2026
- The NYSE cited abnormally low selling price levels under Rule 802.01D
- Q3 2026 net loss was $19.7 million, versus $150.3 million a year earlier
- Cash and equivalents were $26.6 million as of Sept. 30, 2026
Accendra Health Inc. (NYSE: ACH) said the New York Stock Exchange suspended trading in its common stock and has started proceedings to delist it, according to an 8-K accepted Tuesday, Nov. 17, 2026. The company received the NYSE notice on Nov. 16.
The exchange based its decision on Rule 802.01D of the NYSE Listed Company Manual, citing abnormally low selling price levels, the press release filed with the 8-K said. Trading was suspended effective immediately.
Shares move to the over-the-counter market
The common stock began trading on the OTCQB market under the symbol ACCH on Nov. 17. The company said the move will not affect its business operations or its SEC reporting obligations, and does not conflict with or cause an event of default under any of its material debt or other agreements.
This is not the company's first exchange notice this fall. In an 8-K filed Oct. 30, Accendra disclosed an NYSE continued listing notice over market capitalization and stockholders' equity below $50.0 million. The forward-looking statements in the new press release refer to the company's ability to cure noncompliance with NYSE listing standards.
Losses narrowed in the latest quarter but remain large
For the third quarter ended Sept. 30, 2026, revenue was $601.8 million, down 14% from a year earlier. Operating income was $1.3 million, down 95%. The company reported a net loss of $19.7 million, compared with $150.3 million a year earlier, and a diluted loss of $0.25 a share against $1.94.
For the 2025 fiscal year, revenue was $2.76 billion, up 3%, but operating income was $27.5 million after an operating loss of $217.7 million the year before. The net loss was $1.10 billion, wider than the $362.7 million loss in 2024, and the diluted loss per share was $14.31 compared with $4.73.
Cash and equivalents totaled $26.6 million as of Sept. 30, 2026.
Management points to a turnaround
Chief Executive Kenny Gardner-Smith said in the release: "We are focused on taking the necessary steps and implementing decisive measures to support our turnaround and best position the Company for long-term growth and success." He added that the company continues to serve patients and customers and remains committed to its clinical conditions.
The filing does not give a timetable for completing the delisting or say how long the stock will trade on the OTCQB. Investors with questions were directed to Will Parrish, vice president of corporate development and investor relations, at Investor.Relations@accendra.com.
Sources
Written with AI from the company's SEC filing and our market data, and checked against those sources before publishing. Our editorial standards.
More SEC filing stories
Bankruptcies, delistings and restatements →- Presidio Production to Buy Permian Oil and Gas Producers for $360 Million in Cash · FTW · Nov. 19, 2026
- IT Tech Packaging Discloses Going Concern Warning in Audit of 2025 Accounts · ITP · Nov. 20, 2026
- Americas Carmart Extends Lender Waiver and Liquidity Relief to Nov. 22 · CRMT · Nov. 19, 2026
- All In FutureTech Alliance to Buy Chairman's Little Vault for $8 Million in Stock · AIFA · Nov. 19, 2026
More on Accendra Health
ACH page →
Accendra Health Reports Third-Quarter Loss and Trims Full-Year Outlook
The company said full-year net revenue will land at the bottom of its $2.45 billion to $2.55 billion range and adjusted EBITDA could fall as much as 30% below the $310 million midpoint.